Importantly, the combination of ACK1 and KIT inhibitors was found to have a positive therapeutic impact on imatinib-resistant gastrointestinal stromal tumors via anti-proliferative and -migration effect-dependent mechanisms [65], as well as being superior to KRAS-mutant-based therapies in NSCLC [66]. This evidence concerns the gene TNK2 and non-small cell lung carcinoma.